Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Biotech    DIM   FR0013154002

SARTORIUS STEDIM BIOTECH

(DIM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sartorius Stedim Biotech : Technically solid

share with twitter share with LinkedIn share with facebook
share via e-mail
02/13/2020 | 04:01am EST
long trade on a pullback
Conditional Order Terminated
Entry price : 173€ | Target : 193€ | Stop-loss : 169€ | Cancellation Level : 185€ | Potential : 11.56%
Shares in Sartorius Stedim Biotech show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors should buy the stock at current prices near € 173 in order to target the € 193.
Sartorius Stedim Biotech : Sartorius Stedim Biotech : Technically solid
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 50% by 2022.
  • The group's high margin levels account for strong profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 139.9 EUR

Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.

Patrick Rejaunier
© MarketScreener.com 2020
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (EUR)
Sales 2020 1 715 M
EBIT 2020 427 M
Net income 2020 305 M
Debt 2020 161 M
Yield 2020 0,45%
P/E ratio 2020 53,7x
P/E ratio 2021 46,4x
EV / Sales2020 9,72x
EV / Sales2021 8,64x
Capitalization 16 500 M
Upcoming event on SARTORIUS STEDIM BIOTECH
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 165,86  €
Last Close Price 179,00  €
Spread / Highest target 5,59%
Spread / Average Target -7,34%
Spread / Lowest Target -31,3%
EPS Revisions
Managers
NameTitle
Joachim Kreuzburg Chairman, CEO, CFO & Head-Human Resources
Volker Niebel Executive VP-Operations & Information Technology
Oscar-Werner Reif Executive VP-Research & Development
Henri Riey Independent Non-Executive Director
Anne-Marie Graffin Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
SARTORIUS STEDIM BIOTECH23.83%18 300
MEDTRONIC PLC-0.15%149 297
BAXTER INTERNATIONAL INC.7.07%45 710
HOYA CORPORATION3.55%34 616
ZIMMER BIOMET HOLDINGS3.11%31 854
DEXCOM, INC.34.43%26 933